Bevacizumab and Abraxane as Second-line Therapy in Triple Negative Metastatic Breast Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00472693
Recruitment Status : Completed
First Posted : May 14, 2007
Last Update Posted : September 26, 2016
Genentech, Inc.
Information provided by (Responsible Party):
Abramson Cancer Center of the University of Pennsylvania

No Study Results Posted on for this Study
  Recruitment Status : Completed
  Primary Completion Date : April 2011
  Study Completion Date : April 2011